期刊文献+

Anti-tumor Activity of Biodegradable Polymer-paclitaxel Conjugated Micelle Against Mice U14 Cervical Cancers 被引量:4

Anti-tumor Activity of Biodegradable Polymer-paclitaxel Conjugated Micelle Against Mice U14 Cervical Cancers
下载PDF
导出
摘要 Two kinds of paclitaxel(PTX) conjugate micelles,of which one contained 25%(mass fraction) PTX [M(PTX)] and the other contained 22.5%(mass fraction) of PTX and 1.4%(mass fraction) of folate(FA)[FA-M(PTX)],were prepared for cell apoptosis and anti-tumor activity evaluation on U14 cervical cancer mouse models in comparison with 0.9%(mass fraction) saline(control) and equivalent Taxol.Seven days after tail intravenous injection of the drugs,the mice were sacrificed to measure the tumor masses.The average tumor masses were 4.26,2.89,2.63,and 2.17 g for the control,Taxol,M(PTX) and FA-M(PTX) groups,respectively.The inhibition rates of tumor growth calculated for the three drug groups were 32%,38% and 49%,respectively.Flow cytometry(FC) analysis and terminal deoxynucleotidyl transferase(TdT)-mediated deoxyuridine triphosphate(dUTP) nick end labeling(TUNEL) assay were conducted on the cancer tissues.The cell apoptosis rates based on the FC data and the TUNEL data were 20%,31%,37%,42%,and 10%,22%,26%,34%,respectively,both showing statistically significant differences(P〈0.05) between three drug groups and the control group,and between the FA-M(PTX) group and the other two drug groups.In conclusion,the composite FA-M(PTX) micelles can be used for U14 cervical cancer treatment. Two kinds of paclitaxel(PTX) conjugate micelles,of which one contained 25%(mass fraction) PTX [M(PTX)] and the other contained 22.5%(mass fraction) of PTX and 1.4%(mass fraction) of folate(FA)[FA-M(PTX)],were prepared for cell apoptosis and anti-tumor activity evaluation on U14 cervical cancer mouse models in comparison with 0.9%(mass fraction) saline(control) and equivalent Taxol.Seven days after tail intravenous injection of the drugs,the mice were sacrificed to measure the tumor masses.The average tumor masses were 4.26,2.89,2.63,and 2.17 g for the control,Taxol,M(PTX) and FA-M(PTX) groups,respectively.The inhibition rates of tumor growth calculated for the three drug groups were 32%,38% and 49%,respectively.Flow cytometry(FC) analysis and terminal deoxynucleotidyl transferase(TdT)-mediated deoxyuridine triphosphate(dUTP) nick end labeling(TUNEL) assay were conducted on the cancer tissues.The cell apoptosis rates based on the FC data and the TUNEL data were 20%,31%,37%,42%,and 10%,22%,26%,34%,respectively,both showing statistically significant differences(P〈0.05) between three drug groups and the control group,and between the FA-M(PTX) group and the other two drug groups.In conclusion,the composite FA-M(PTX) micelles can be used for U14 cervical cancer treatment.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2012年第4期656-661,共6页 高等学校化学研究(英文版)
基金 Supported by the National Natural Science Foundation of China(Nos.20674084,21004062,51103148) the National Basic Research Program of China(No.2009CB930102) the National High-Tech Research and Development Program of China(No.2007AA03Z535)
关键词 Cervical cancer Polymer-drug conjugate PACLITAXEL Folic acid Targeted drug delivery Cervical cancer Polymer-drug conjugate Paclitaxel Folic acid Targeted drug delivery
  • 相关文献

参考文献18

  • 1Ito T., Ishizuka T., Suzuki K., Ikoma Y., Saito J., Onuma M., Miwa T., Hashiba Y., Kuno N., Horibe N., Mizuno K., Ishikawa K., Kaze?to S., Arch. Gyneeol. Obstet., 2000, 264, 68.
  • 2Max A., Clark D.O., William N., Markert R. J., Dodson M. G., Am. J. Clin. Oneol., 1991, 14(4), 352.
  • 3Ceruti M., Crosasso P., Brusa P., Arpicco S., Dosie F., Cattel L., J. Control. Release, 2000, 63,141.
  • 4Lluch A., Ojeda B., Colomer R., Barnadas A., Massuti B., Casado A., Angeles c, Maroto P., Cancer, 2000, 89(11), 2169.
  • 5Koziara J. M., Lockman P. R, Allen D. D., Mumper R. J., J. Control. Release, 2004, 99, 259.
  • 6Arriagada J. D., Barthelemy R., Bonner N., Bonomi J., Enami P., Minatel B., Park E., Quoix K. E., van Houtte P., Lung Cancer, 1997, 17(1),823.
  • 7Thigpen J. T., Semin. Oncol., 2000, 27(3), 11.
  • 8Chang A. Y. C., Rubins J., Asbury R., Boros L., Hui L. F., Edelman D. Z., Anteby S. 0., Peretz T., Semin. Oneol., 2001, 28(4),10.
  • 9Rowinsky E. K., Donehower R c, New Engl. J. Med., 1995, 332(15),1004.
  • 10Weiss R. B., Donehower R. C., Wiemik P. H., Ohnuma T., Gralla R. J., Trump D. L., Baker J. R Jr., van Echo D. A., von Hoff D. D., Leyland-Jones B., J. Clin. Oneol., 1990,8(7), 1263.

同被引文献9

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部